A Novel De-escalation Antiplatelet Therapy for Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention

Overview

Journal Medicine (Baltimore)

Specialty General Medicine

Date 2023 Jul 7

PMID 37417626

Authors

Yachao Li

Mengjie Lei

Yanli Yang

Lei An

Haili Zhou

Jingyao Wang

Zhigang Zhao

Xiangjin Wang

Shaoping Nie

Xiao Wang

William Kongto Hau

Zengming Xue

Affiliations

Soon will be listed here.

Abstract

To investigate the effect of different DAPTs in patients with ACS undergoing PCI, and to identify the most efficient DAPT to reduce the risk of ischemia and bleeding after PCI. Between March 2017 and December 2021, 1598 patients with ACS who underwent PCI were included in the study. The DAPT protocol included the clopidogrel group (aspirin 100 mg + clopidogrel 75 mg), ticagrelor group (aspirin 100 mg + ticagrelor 90 mg), de-escalation Group 1 (reduced dose of ticagrelor [from 90 mg to 60 mg]) after 3 months of oral DAPT [aspirin 100 mg + ticagrelor 90 mg]), and de-escalation Group 2 (switched from ticagrelor to clopidogrel after 3 months of oral DAPT [aspirin 100 mg + ticagrelor 90 mg]). All patients received a 12-month follow-up. The primary endpoint was net adverse clinical events (NACEs) that included the composite endpoints of cardiac death, myocardial infarction, ischemia-driven revascularization, stroke, and bleeding events. There were 2 secondary endpoints, major adverse cardiovascular and cerebrovascular events (MACCEs) and bleeding. No statistically significant difference was found in the incidence of NACEs between the 4 groups at the average 12-month follow-up (15.7% vs 19.2% vs 16.7% vs 20.4%). Cox regression analysis revealed that DAPT ticagrelor group regimen (hazard ratio [HR] 0.547; 95% confidence interval [CI]: 0.334-0.896; P = .017) were associated with a lower risk of MACCEs. Age (HR 1.024; 95% CI: 1.003-1.046; P = .022). DAPT de-escalation Group 2 regimen (HR 1.665; 95% CI: 1.001-2.767; P = .049) were marginally associated with a higher risk of MACCEs. Ticagrelor group regimen (HR 1.856; 95% CI: 1.376-2.504; P < .001) was associated with higher risk of bleeding events. Ticagrelor group regimen (HR 1.606; 95% CI: 1.179-2.187; P = .003) were associated with a higher risk of minor bleeding events. For patients with ACS underwent PCI, there were no significant difference in the incidence of NACEs between 3 and 12 months after PCI between de-escalation and non-de-escalation therapies. Compared with ticagrelor-based 12-month DAPT, there was no significant difference in MACCEs and bleeding events in patients receiving de-escalation treatment (ticagrelor reduction from 90 to 60 mg, 3 months after PCI).

References

Zhang H, Ke J, Huang J, Xu K, Chen Y . Short- versus long-term dual antiplatelet therapy after second-generation drug-eluting stent implantation in patients with diabetes mellitus: A meta-analysis of randomized controlled trials. PLoS One. 2020; 15(12):e0242845. PMC: 7743959. DOI: 10.1371/journal.pone.0242845. View

Ibanez B, James S, Agewall S, Antunes M, Bucciarelli-Ducci C, Bueno H . 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European.... Eur Heart J. 2017; 39(2):119-177. DOI: 10.1093/eurheartj/ehx393. View

Wallentin L, Becker R, Budaj A, Cannon C, Emanuelsson H, Held C . Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009; 361(11):1045-57. DOI: 10.1056/NEJMoa0904327. View

Rodriguez F, Harrington R . Management of Antithrombotic Therapy after Acute Coronary Syndromes. N Engl J Med. 2021; 384(5):452-460. PMC: 9275395. DOI: 10.1056/NEJMra1607714. View

Prejean S, Din M, Reyes E, Hage F . Guidelines in review: Comparison of the 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes and the 2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without.... J Nucl Cardiol. 2017; 25(3):769-776. DOI: 10.1007/s12350-017-1137-z. View

Kernan W, Ovbiagele B, Black H, Bravata D, Chimowitz M, Ezekowitz M . Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2014; 45(7):2160-236. DOI: 10.1161/STR.0000000000000024. View

Angiolillo D, Rollini F, Storey R, Bhatt D, James S, Schneider D . International Expert Consensus on Switching Platelet P2Y Receptor-Inhibiting Therapies. Circulation. 2017; 136(20):1955-1975. DOI: 10.1161/CIRCULATIONAHA.117.031164. View

Raposeiras-Roubin S, Faxen J, Iniguez-Romo A, Paulo Simao Henriques J, DAscenzo F, Saucedo J . Development and external validation of a post-discharge bleeding risk score in patients with acute coronary syndrome: The BleeMACS score. Int J Cardiol. 2018; 254:10-15. DOI: 10.1016/j.ijcard.2017.10.103. View

Collet J, Thiele H, Barbato E, Barthelemy O, Bauersachs J, Bhatt D . 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2020; 42(14):1289-1367. DOI: 10.1093/eurheartj/ehaa575. View

10.

Colombo A, Chieffo A, Frasheri A, Garbo R, Masotti-Centol M, Salvatella N . Second-generation drug-eluting stent implantation followed by 6- versus 12-month dual antiplatelet therapy: the SECURITY randomized clinical trial. J Am Coll Cardiol. 2014; 64(20):2086-97. DOI: 10.1016/j.jacc.2014.09.008. View

11.

Mauri L, Kereiakes D, Yeh R, Driscoll-Shempp P, Cutlip D, Steg P . Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med. 2014; 371(23):2155-66. PMC: 4481318. DOI: 10.1056/NEJMoa1409312. View

12.

Han Y, Chen J, Qiu M, Li Y, Li J, Feng Y . Predicting long-term ischemic events using routine clinical parameters in patients with coronary artery disease: The OPT-CAD risk score. Cardiovasc Ther. 2018; 36(5):e12441. DOI: 10.1111/1755-5922.12441. View

13.

Bonaca M, Bhatt D, Cohen M, Steg P, Storey R, Jensen E . Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med. 2015; 372(19):1791-800. DOI: 10.1056/NEJMoa1500857. View

14.

Tan J, Chew D, Kader M, Ako J, Bahl V, Chan M . 2020 Asian Pacific Society of Cardiology Consensus Recommendations on the Use of P2Y Receptor Antagonists in the Asia-Pacific Region. Eur Cardiol. 2021; 16:e02. PMC: 7941380. DOI: 10.15420/ecr.2020.40. View

15.

Rao A, Pratt C, Berke A, Jaffe A, Ockene I, Schreiber T . Thrombolysis in Myocardial Infarction (TIMI) Trial--phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. J Am Coll Cardiol. 1988; 11(1):1-11. DOI: 10.1016/0735-1097(88)90158-1. View

16.

Kubica J, Adamski P, Buszko K, Baranska M, Sikora J, Marszall M . Platelet inhibition with standard vs. lower maintenance dose of ticagrelor early after myocardial infarction (ELECTRA): a randomized, open-label, active-controlled pharmacodynamic and pharmacokinetic study. Eur Heart J Cardiovasc Pharmacother. 2019; 5(3):139-148. DOI: 10.1093/ehjcvp/pvz004. View

17.

Jin C, Kim M, Song K, Jin X, Lee K, Park J . Pharmacodynamics and Outcomes of a De-Escalation Strategy with Half-Dose Prasugrel or Ticagrelor in East Asians Patients with Acute Coronary Syndrome: Results from HOPE-TAILOR Trial. J Clin Med. 2021; 10(12). PMC: 8234416. DOI: 10.3390/jcm10122699. View

18.

Escaned J, Cao D, Baber U, Nicolas J, Sartori S, Zhang Z . Ticagrelor monotherapy in patients at high bleeding risk undergoing percutaneous coronary intervention: TWILIGHT-HBR. Eur Heart J. 2021; 42(45):4624-4634. DOI: 10.1093/eurheartj/ehab702. View

19.

Storey R, Angiolillo D, Bonaca M, Thomas M, Judge H, Rollini F . Platelet Inhibition With Ticagrelor 60 mg Versus 90 mg Twice Daily in the PEGASUS-TIMI 54 Trial. J Am Coll Cardiol. 2016; 67(10):1145-1154. DOI: 10.1016/j.jacc.2015.12.062. View

20.

Gaubert M, Laine M, Richard T, Fournier N, Gramond C, Bessereau J . Effect of ticagrelor-related dyspnea on compliance with therapy in acute coronary syndrome patients. Int J Cardiol. 2014; 173(1):120-1. DOI: 10.1016/j.ijcard.2014.02.028. View